Tranexamic acid use and risk of thrombosis in regular users of antithrombotics undergoing primary total knee arthroplasty: a prospective cohort study

被引:11
作者
Hourlier, Herve [1 ]
Fennema, Peter [2 ]
机构
[1] Polyclin Thierache, Dept Orthopaed Surg, Wignehies, France
[2] AMR, Mannedorf, Switzerland
关键词
tranexamic acid; total knee arthroplasty; blood transfusion; rivaroxaban; RANDOMIZED CLINICAL-TRIAL; TOTAL HIP-ARTHROPLASTY; ANTIFIBRINOLYTIC AGENTS; ORTHOPEDIC-SURGERY; UNITED-STATES; METAANALYSIS; REPLACEMENT; THERAPY; COMPLICATIONS; TRANSFUSION;
D O I
10.2450/2016.0160-16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The effect of tranexamic acid has not been examined in patients who are regular users of antithrombotics before undergoing total knee arthroplasty. The aim of this study was to determine the impact of tranexamic acid on bleeding and the risk of transfusion and thrombosis in patients taking an antithrombotic treatment before primary unilateral total knee arthroplasty. Material and methods. A prospective observational study was conducted in a series of 385 consecutive primary total knee arthroplasties performed with and without the administration of tranexamic acid. We compared post-operative bleeding, as determined by a bleeding index, and postoperative haemoglobin and haematocrit between patients taking an antithrombotic treatment before the operation (ATT+group) and those naive or non-regular users of antithrombotics (ATT-group). Post-operatively, rivaroxaban was prescribed for deep vein thrombosis prophylaxis, unless contraindicated. Antiplatelet therapy and vitamin K antagonist anticoagulants were not resumed during the early post-operative period. Results. The prevalence of total knee arthroplasty performed in patients who are regular users of antithrombotics was 33%. Tranexamic acid was administered during 62% of the arthroplasties in the ATT+group and to 90% in the ATT-group. In both study groups, the bleeding index was significantly lower in patients who received tranexamic acid, both in the ATT+(p<0.001) and in the ATT-group (p=0.001). No patients in the ATT+group received a blood transfusion during the first post-operative week. No thrombotic complications were identified for up to 2 months in the ATT+group. Discussion. Tranexamic acid use after the induction of general anaesthesia in total knee arthroplasty represents a fast, inexpensive, and effective opportunity to reduce peri-operative blood loss in patients on chronic antithrombotic treatment undergoing total knee arthroplasty.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 31 条
  • [1] Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Andreotti, Felicita
    Rocca, Bianca
    Husted, Steen
    Ajjan, Ramzi A.
    ten Berg, Jurrien
    Cattaneo, Marco
    Collet, Jean-Philippe
    De Caterina, Raffaele
    Fox, Keith A. A.
    Halvorsen, Sigrun
    Huber, Kurt
    Hylek, Elaine M.
    Lip, Gregory Y. H.
    Montalescot, Gilles
    Morais, Joao
    Patrono, Carlo
    Verheugt, Freek W. A.
    Wallentin, Lars
    Weiss, Thomas W.
    Storey, Robert F.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (46) : 3238 - +
  • [2] [Anonymous], RIV PREV VEN THROMB
  • [3] [Anonymous], 2011, COCHRANE DATABASE SY
  • [4] Bloomfield Michael R, 2011, Am J Orthop (Belle Mead NJ), V40, pE148
  • [5] Antithrombotic Therapy in the Elderly
    Capodanno, Davide
    Angiolillo, Dominick J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (21) : 1683 - 1692
  • [6] Warfarin management in patients on continuous anticoagulation therapy undergoing total knee replacement
    Chana, R.
    Salmon, L.
    Waller, A.
    Pinczewski, L.
    [J]. JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2011, 93B (11): : 1497 - 1502
  • [7] Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials
    Cid, J
    Lozano, M
    [J]. TRANSFUSION, 2005, 45 (08) : 1302 - 1307
  • [8] Aspirin in Patients Undergoing Noncardiac Surgery
    Devereaux, P. J.
    Mrkobrada, M.
    Sessler, D. I.
    Leslie, K.
    Alonso-Coello, P.
    Kurz, A.
    Villar, J. C.
    Sigamani, A.
    Biccard, B. M.
    Meyhoff, C. S.
    Parlow, J. L.
    Guyatt, G.
    Robinson, A.
    Garg, A. X.
    Rodseth, R. N.
    Botto, F.
    Buse, G. Lurati
    Xavier, D.
    Chan, M. T. V.
    Tiboni, M.
    Cook, D.
    Kumar, P. A.
    Forget, P.
    Malaga, G.
    Fleischmann, E.
    Amir, M.
    Eikelboom, J.
    Mizera, R.
    Torres, D.
    Wang, C. Y.
    VanHelder, T.
    Paniagua, P.
    Berwanger, O.
    Srinathan, S.
    Graham, M.
    Pasin, L.
    Le Manach, Y.
    Gao, P.
    Pogue, J.
    Whitlock, R.
    Lamy, A.
    Kearon, C.
    Baigent, C.
    Chow, C.
    Pettit, S.
    Chrolavicius, S.
    Yusuf, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) : 1494 - 1503
  • [9] Ninety-Day Morbidity in Patients Undergoing Primary TKA With Discontinuation of Warfarin and Bridging With LMWH
    Gibon, Emmanuel
    Barut, Nicolas
    Anract, Phillipe
    Courpied, Jean-Pierre
    Hamadouche, Moussa
    [J]. JOURNAL OF ARTHROPLASTY, 2014, 29 (06) : 1185 - 1188
  • [10] The use of antifibrinolytic agents in total hip arthroplasty - A meta-analysis
    Gill, J. Brian
    Rosenstein, Alexander
    [J]. JOURNAL OF ARTHROPLASTY, 2006, 21 (06) : 869 - 873